ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.36
0.17%
US Tech 100
20,897.60
0.84%
S&P 500
6,037.88
0.72%
US Dollar vs CAD
1.43346
0.00%
Bitcoin
98,175.39
0.32%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. NewAmsterdam Pharma Company NV (NAMSW)

  7. NewAmsterdam Pharma Company NV (NAMSW) News

NAMSW

NewAmsterdam Pharma Comp... (NAMSW)

NewAmsterdam Pharma Company NV
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NAMSW
DateTimeSourceHeadlineSymbolCompany
01/29/20257:00AMGlobeNewswire Inc.NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech ConferenceNASDAQ:NAMSWNewAmsterdam Pharma Company NV
01/10/20253:26PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
01/10/20257:27AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
01/10/20257:00AMGlobeNewswire Inc.NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic PrioritiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
01/09/20252:38PMGlobeNewswire Inc.NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NAMSWNewAmsterdam Pharma Company NV
01/08/20254:58PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
01/07/20254:21PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
01/07/20254:21PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
01/07/20254:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
01/07/20253:29PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NAMSWNewAmsterdam Pharma Company NV
01/06/20254:56PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
01/06/20254:54PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
01/06/20254:48PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
12/13/20244:16PMGlobeNewswire Inc.NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
12/13/20247:28AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
12/13/20245:33AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NAMSWNewAmsterdam Pharma Company NV
12/11/20248:37PMGlobeNewswire Inc.NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
12/11/20246:57PMEdgar (US Regulatory)Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)]NASDAQ:NAMSWNewAmsterdam Pharma Company NV
12/10/20243:48PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NAMSWNewAmsterdam Pharma Company NV
12/10/20243:34PMGlobeNewswire Inc.NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
12/10/20243:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
12/10/20246:24AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
12/10/20246:00AMGlobeNewswire Inc.NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial HypercholesterolemiaNASDAQ:NAMSWNewAmsterdam Pharma Company NV
12/06/20243:01PMGlobeNewswire Inc.NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NAMSWNewAmsterdam Pharma Company NV
11/20/20246:07AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
11/20/20246:00AMGlobeNewswire Inc.NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFHNASDAQ:NAMSWNewAmsterdam Pharma Company NV
11/18/20243:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
11/18/20242:20PMGlobeNewswire Inc.NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024NASDAQ:NAMSWNewAmsterdam Pharma Company NV
11/13/20243:23PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
11/06/20247:00AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NAMSWNewAmsterdam Pharma Company NV
 Showing the most relevant articles for your search:NASDAQ:NAMSW

Your Recent History

BOV
A1AP34M
Advance Auto Parts
BIT
UB7RUP
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads